m+Medelevator.RU
← Поиск публикаций
Frontiers in cardiovascular medicine · 2026

Impact of an early, graduated mobilization program on recovery and postoperative outcomes after cardiac revascularization with extracorporeal circulation.

СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Liu Jiaqi, Jiang Mi, Zhao Xuewen, Liang Yingdan, Liu Ying, Pan Ruijin

Аннотация

OBJECTIVE: This randomized controlled trial evaluated the effects of an early, graduated mobilization program on functional recovery (primary endpoint: postoperative day-5 forced vital capacity [FVC]; secondary endpoints: activities of daily living [ADL] scores, handgrip strength, Short Physical Performance Battery [SPPB] scores, postoperative pulmonary complications [PPCs], and postoperative length of stay) in patients undergoing on-pump coronary artery bypass grafting (CABG).

METHODS: Between March to September 2025, 92 patients underwent on-pump CABG; after screening, 80 consecutive eligible patients (sample size calculated based on PPC incidence, n = 42 per group before attrition adjustment) were randomized 1:1 using a random number table with allocation concealment to a control group (n = 40) or an intervention group (n = 40).

RESULTS: On postoperative day 5, the intervention group demonstrated significantly better FVC, ADL scores, handgrip strength, and SPPB scores (all P < 0.05). PPC incidence was markedly lower (10% vs. 62.5%, P < 0.0001), and postoperative length of stay was shorter (7.13 ± 2.36 vs. 9.18 ± 2.66 days, P = 0.0006).

CONCLUSION: The early graduated mobilization program was safe, feasible, and associated with improved short-term functional recovery, reduced PPCs, and shorter postoperative hospital stay after on-pump CABG. Larger multicenter studies with longer follow-up are required to confirm long-term safety and effectiveness.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты